Data analysis on gene set enrichment analysis revealed that p53 R248 and R282 mutations significantly upregulate CYP3A4 mRNA and protein levels, and cancer cell lines bearing these two p53 mutations displayed resistance effects to several CYP3A4-metabolized chemotherapeutic drugs.36 These results ascertained this protein-coding gene as a downstream factor of these two mutants' regulatory profile. This evidence concerns the gene TP53 and cancer.